Core Viewpoint - The healthcare services sector experienced a decline of 1.45% with a net outflow of 1,102.31 million in funds, indicating a bearish trend in the market [1] Group 1: Sector Performance - The healthcare services sector saw a total of 2 stocks rising and 41 stocks declining [1] - The top ten decliners in the sector included Sanbo Brain Science (-4.57%), Ruizhi Medicine (-4.56%), and Innovation Medical (-4.34%) [1] Group 2: Stock Details - Sanbo Brain Science closed at 49.87 with a decline of 4.57% and a net fund outflow of 108.09 million [1] - Ruizhi Medicine closed at 10.88, down 4.56%, with a net outflow of 68.69 million [1] - Innovation Medical closed at 15.00, down 4.34%, with a net outflow of 320.40 million [1] - Other notable decliners included Maipu Medical (-3.79%), Nuotai Biological (-3.40%), and Dae Oriental (-3.21%) [1] Group 3: Gainers - The stocks that gained included *ST Biological with an increase of 3.83% and Chengda Pharmaceutical with an increase of 1.03% [1]

Market Performance - The brain-computer interface concept declined by 2.60%, ranking among the top declines in concept sectors [1][2] - Within the sector, companies such as Xiangyu Medical and Aipeng Medical experienced significant declines, while Lepu Medical and ST Huaton saw increases of 4.05% and 3.05% respectively [1][3] Capital Flow - The brain-computer interface sector experienced a net outflow of 2.376 billion yuan, with 27 stocks seeing net outflows and 5 stocks exceeding 100 million yuan in outflows [2] - The company with the highest net outflow was Jihua Group, with a net outflow of 998.798 million yuan, followed by Innovation Medical and Haige Communication with net outflows of 288.118 million yuan and 186.919 million yuan respectively [2][3] Top Gainers and Losers - The top gainers in the brain-computer interface sector included Lepu Medical with a gain of 4.05% and ST Huaton with a gain of 3.05% [1][3] - The top losers included Xiangyu Medical with a decline of 8.34% and Aipeng Medical with a decline of 6.17% [3]

证券代码：002173 证券简称：创新医疗 公告编号：2025-033 创新医疗管理股份有限公司 关于签署参股公司全诊医学《B 轮增资及转股协议》 《B 轮股东协议》及相关文件的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、本次交易概述 （一）交易基本情况 创新医疗管理股份有限公司（以下简称"公司"）于 2024 年 8 月 28 日召开 的第六届董事会 2024 年第六次临时会议，审议通过了《关于投资杭州全诊医学 科技有限公司的议案》，同意公司对杭州全诊医学科技有限公司（以下简称"全 诊医学"）进行战略投资，具体内容详见公司 2024 年 8 月 29 日、2024 年 11 月 1 日发布于巨潮资讯网（http://www.cninfo.com.cn）的相关公告。 议》约定在规定时间内设立员工期权计划（对应全诊医学在本次融资交易和员工 持股平台增资后 5%的股权）。 根据《深圳证券交易所股票上市规则》、公司《章程》等相关规定，本次交 易事项无需提交股东大会审议。 （三）本次交易事项不涉及关联交易，也不构成《上市公司重大资产组管理 办法》规定的重 ...

证券代码：002173 证券简称：创新医疗 公告编号：2025-032 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 创新医疗管理股份有限公司（以下简称"公司"）第六届董事会于 2025 年 6 月 30 日召开了 2025 年第五次临时会议。本次会议以通讯表决方式召开。会议通 知于 2025 年 6 月 27 日以书面形式发出。本次会议由陈海军董事长主持，应出席 董事 9 名，实际出席 9 名。本次会议召开符合《公司法》及公司《章程》的规定， 合法有效。 特此公告。 创新医疗管理股份有限公司 创新医疗管理股份有限公司 第六届董事会 2025 年第五次临时会议决议公告 二、董事会会议审议情况 与会董事就议案进行了审议、表决，以 9 票赞成、0 票反对、0 票弃权的表 决结果一致通过了《关于同意签署参股公司全诊医学〈B 轮增资及转股协议〉〈B 轮股东协议〉及相关文件的议案》。 同意公司签署《杭州全诊医学科技有限公司 B 轮增资及转股协议》、《杭州全 诊医学科技有限公司 B 轮股东协议》以及杭州全诊医学科技有限公司（以下简称 "全诊医学" ...

Group 1 - The brain-computer interface (BCI) sector is experiencing strong performance, with companies like Innovation Medical and Sairui Medical hitting their daily price limits [1] - Neuralink has successfully implanted BCI devices in 7 individuals, allowing them to interact with external environments through brain signals, including controlling video games [1] - Some participants can control robotic arms for precise tasks, showcasing the potential of BCI technology in medical rehabilitation for patients with spinal cord injuries and ALS [1] Group 2 - Neuralink uses a customized robotic arm for surgery, implanting the N1 chip, which is the size of a coin and collects brain signals via microelectrodes [2] - The BCI technology is considered one of the most disruptive innovations of the 21st century, with significant breakthroughs in recent years, including FDA approval for human trials and advancements from companies like Meta [2] - Domestic companies are actively investing in the BCI field, with Innovation Medical's partner Boling focusing on BCI technology and high-end medical device development, expecting market sales by 2025 [2]

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing significant growth, driven by advancements from companies like Neuralink and recent breakthroughs in China, indicating a potential commercialization of BCI technology in the near future [2][4][5]. Group 1: Neuralink Developments - Neuralink has showcased its latest research and product development, with 7 participants currently using the device for an average of 50 hours per week, peaking over 100 hours [2]. - The company plans to implant devices in the speech cortex by the end of 2025 to decode silent speech from brain signals, and aims to increase electrode channels to 3,000 by 2026 to explore restoring vision [2][3]. - By 2028, Neuralink anticipates implanting over 25,000 electrodes to address mental health issues and explore integration with AI, potentially allowing humans to control robots directly [3]. Group 2: Market Potential and Growth - The global BCI market is projected to grow from $2.62 billion in 2024 to approximately $12.4 billion by 2034, with a compound annual growth rate (CAGR) of 17.35% [4]. - The BCI technology is recognized as one of the most disruptive technologies of the 21st century, with expectations for a surge in medical product applications over the next 5 to 10 years [4]. Group 3: Domestic Developments in China - Recent successful trials in China, including the first invasive BCI-assisted rehabilitation for a stroke patient, highlight the rapid advancement of BCI technology towards commercialization [4]. - The "Beijing Brain Institute" has developed a flexible, high-throughput, semi-invasive BCI system that has entered clinical trials, marking significant progress in the field [4]. Group 4: Industry Insights - The domestic BCI industry is benefiting from technological breakthroughs and supportive government policies, which are expected to accelerate the commercialization process [5]. - BCI products are categorized into non-invasive and invasive types, with non-invasive products leading in commercialization, while invasive products are still in clinical research stages [6]. - Despite the promising outlook, the BCI industry faces challenges related to safety, regulatory approval, and the need for foundational research [6][7].

Core Viewpoint - The brain-computer interface sector has seen a significant increase of 5.17%, ranking second among concept sectors, with 30 stocks rising, including notable gains from Xiangyu Medical and others [1][2]. Sector Performance - The brain-computer interface sector recorded a daily increase of 5.17%, with the top-performing stocks including Xiangyu Medical (20% limit up), Jihua Group, Innovation Medical, and Rongtai Health, all hitting the limit up [1][2]. - Other notable gainers in the sector included Aipeng Medical (10.82%), Mailande (8.71%), and Yingqu Technology (7.79%) [1]. Capital Flow - The brain-computer interface sector attracted a net inflow of 606 million yuan from main funds, with 19 stocks receiving net inflows, and 6 stocks exceeding 50 million yuan in net inflow [2]. - Innovation Medical led the sector with a net inflow of 312 million yuan, followed by Lepu Medical, Rongtai Health, and Hanwei Technology with net inflows of 99.42 million yuan, 74.91 million yuan, and 65.52 million yuan respectively [2][3]. Capital Inflow Ratios - Jihua Group and Rongtai Health had the highest net inflow ratios at 29.79% and 22.35% respectively, indicating strong investor interest [3]. - Other companies with notable inflow ratios included Junpu Intelligent (18.98%) and Innovation Medical (17.73%) [3].

Market Overview - The market experienced a rebound with the ChiNext Index leading the gains. The military industry sector saw significant growth, with over 20 stocks including Changcheng Military and Hunan Tianyan hitting the daily limit. The stablecoin concept also surged, with stocks like Hopu Co. and Xiexin Energy reaching their limits. Brain-computer interface stocks rose, with Xiangyu Medical and Innovation Medical hitting the limit. Overall, more than 4,000 stocks in Shanghai and Shenzhen markets were in the green, with a total transaction volume of 1.51 trillion [1]. Hot Topics Military Industry - The military sector continued its upward trend, with stocks like Changcheng Military, Feiyada, and Zhongguang Defense hitting consecutive limits. Hunan Tianyan and Beifang Navigation also saw significant rebounds [4]. RWA (Real World Assets) - The RWA sector experienced substantial gains, with stocks like Hopu Co. and Hangzhou Garden hitting their limits. The market is witnessing a rapid growth of RWA ecosystem participants, including issuers, custodial banks, and investors, which may present investment opportunities in asset operation, banking IT, and cross-border payments [6][8]. Brain Science - The brain science sector saw significant increases, with stocks like Rongtai Health and Innovation Medical hitting their limits. Recent developments from Neuralink, including clinical trials for brain-computer interfaces, have generated excitement in the market. The brain-computer interface market in China is projected to reach 3.2 billion by 2024 and exceed 5.5 billion by 2027, with global applications expected to reach between 40 billion to 145 billion by 2030-2040 [9][10][11].

Market Overview - The A-share market experienced a significant rebound on June 30, with the Shanghai Composite Index rising by 0.59%, the Shenzhen Component Index by 0.83%, and the ChiNext Index by 1.35% [2] - A total of 4,056 companies saw their stock prices increase, while 1,127 companies declined, with 92 stocks hitting the daily limit up [3][4] - In the first half of the year, the Shanghai Composite Index rose by 2.76%, and the North Star 50 Index surged by 39.45%, reaching a historical high [3] Sector Performance - The military industry sector saw a notable surge, with stocks like Great Wall Military Industry and North Navigation hitting the daily limit up. This was influenced by the upcoming grand military parade on September 3, showcasing domestically produced main battle equipment [5] - The brain-computer interface sector also experienced a rise, with stocks such as Xiangyu Medical and Innovation Medical reaching the daily limit up. This was driven by Neuralink's recent developments and future plans for human-machine integration [7][8] Gaming Industry - The gaming sector saw a significant increase following the announcement of 147 domestic game approvals and 11 imported game approvals by the National Press and Publication Administration, marking a record high for monthly approvals in recent years. Major companies like Tencent and NetEase received approvals [9] - Citic Securities expressed optimism about the gaming sector, highlighting that the core companies' valuations are significantly lower than those in the new consumption sector, suggesting potential growth [9] Trade Developments - Positive trade news emerged as Canada lifted its digital services tax on tech companies, aiming to restart negotiations with the U.S. [9] - India's trade team extended its stay in Washington to resolve differences, with hopes of reaching a temporary agreement before the July 9 deadline [10]

Group 1 - The core objective of the delegation visit from various countries is to deepen international medical cooperation and explore development opportunities in cross-border medical services and innovative medical devices [1][2] - There is a growing demand for high-quality traditional Chinese medicine (TCM) services in Russia and surrounding countries, with proposals for business medical tours and international medical tourism [1][2] - Shanghai Pudong Hospital aims to become a significant engine for cross-border medical services and a model project for internationalization and marketization in the context of consumption upgrade trends [2] Group 2 - The Pudong Hospital is the largest medical education and research center in the southern part of the Pudong New Area, with plans to integrate resources from Fudan University and leverage the advantages of the Lingang New Area [2] - The Lingang New Area Medical Device Innovation Center is looking to establish comprehensive cooperation with Shanghai Pudong Hospital in areas such as medical device testing and TCM diagnosis [2] - The recent signing ceremony for cross-border medical cooperation projects marks a significant step in building a network for cross-border medical services, education, and insurance [1]